Ekf Diagnostics Share Discussion Threads

[tongosti] 15/2/2022 14:47

WAN's div yield must be more and more attractive (for him and gm's of the world) by the hour now innit. Lol

[wan] 15/2/2022 10:19

Staying with the UK (which I appreciate is nothing to get too excited about, but it's perhaps one to watch) -

Recently I noticed that a leading company in the supply, logistics and support of point of care medical diagnostic devices and consumables to the UK Healthcare sector, started selling an EKF product, the 'Prospect' Hemo Control -


Today I was catching up with a line of research and I noticed that Prospect Diagnostics appear to have launched/made available an EKF private label product too, otherwise known as EKF's DiaSpect Tm -

[tongosti] 15/2/2022 08:52

55 printing.

That’s some direction of travel innit.

P.S. there is an idiot following me around these boards. he/she changes aliases constantly. recently calling oneself drew - just letting you know folks.

[wan] 15/2/2022 08:30

Direction of travel -

The following article exemplifies the global opportunity in my view, from a molecular testing perspective (albeit I seem to have been waiting a long time for it to come to pass proper in the UK in terms of diagnostics generally!), but as a result of pandemic the dynamics have materially changed, let's see if the UK realises it and acts on the clear benefits of prevention!

How COVID-19 has helped revolutionise UK diagnostics

BY ADRIAN SMITH 14 FEBRUARY 2022

Adrian Smith, general manager, Hologic UK and Ireland, explains how the pandemic has helped the industry act with clarity and determination to revolutionise UK diagnostics.

The COVID-19 pandemic has shown us the importance of building a health service focused on prevention rather than cure and technological advances in the diagnostics sector, including automated on-demand molecular testing, is set to significantly improve the health outcomes of millions of patients.

We know that preventing disease has many benefits over curing it. The UK Government published its vision in 2018 to transform the UK’s approach, stating that around £14 of social benefit comes for every £1 spent across a broad range of areas of prevention. But despite this clear benefit, the government’s own findings showed that we spent 60% of public funding for healthcare on cure and rehabilitation, and only 5% on prevention. That amounted to £97 billion a year on treating diseases, and only £8 billion on preventing them.

So, where should the focus lie when it comes to redesigning a health system that prioritises prevention?

At the heart of earlier detection, diagnosis, and prevention lies diagnostics, also echoed in the government’s Life Science’s Vision. And if you look at the innovation in the molecular diagnostics field, you will see three powerful forces reframing perceptions of what is possible.

Increasing adoption of new molecular diagnostic platforms

Of course, with every new technology, there are challenges to overcome. These new approaches are more expensive and moving away from traditional tried-and-tested approaches always takes time. But the direction of travel is clear. Modern molecular diagnostic platforms are quickly rising to the ascendancy when it comes to identifying infectious and testing diseases.

Full story -

[tongosti] 15/2/2022 08:05

Delusions are a very powerful force in the markets.Charles MacKay's "Extraordinary delusions and the madness of crowds" is a book everyone should read.

[wan] 15/2/2022 07:58

Excellent news today over at Verici, which is a very important step towards product commercialisation.

And confirms that the positive direction of travel, in terms of development and commercialisation, continues, with more to follow before the end of the current quarter ending March 31st (not that I think the trend will stop there!).

I also believe that options abound in terms of an accelerated commercialisation strategy. Today's news will help increase those options!

Option 1 - Verici already has a CLIA waived lab

Option 2 - So do EKF

Option 3 - Many other partnering opportunities!

[sirshagalot] 11/2/2022 11:36

I have turnaround @ 54-55p range i will prob buy into this again.
Tongi,s call was correct and he that bends with the winds survives to invest again.
In my opinion 48p is a little too low for me, but hey thats why you see cars for sale @ £19,999.99 .
"Caveat emptor" and all that jazz.

[tongosti] 11/2/2022 10:41

When I made the original 48p call this was at 71. More than half way there.

[wan] 09/2/2022 09:58

For those interested, this video recorded in October 2021 is the most recent update from Purissima, describing (to a degree) the benefits of their technology that utilises fermentation which is hugely scalable, indicating that their first two products (among many others planned) were imminent -

[tongosti] 09/2/2022 09:15

Amazed a few take this chap's arguments seriously. Live and let live - it takes two to make a market ain't it. PS. His buying the absolute lows in March 2020 is up there - just when one thinks has heard it all!

[tongosti] 09/2/2022 08:54

Phenomenal day in the wider markets. Thought rising tide lifts all boats? It does but only the solid ones apparently. mg - commiserations.

[tongosti] 08/2/2022 11:49

58 printing - Mr Market gave wans of the world enough warnings in advance folks. Hardly a shocker.

[tongosti] 04/2/2022 15:02

1- Markets were disappointed with the latest company report. If that fundamental release didn't do the trick, what will?2- Even in good wider market days, this share goes down - such poor relative strength is very telling and it's one of the very few statistics that has genuine (ex-ante) predicting power in markets3 - The breakdown from a 15 month range, makes very clear the likely path of least resistance 4 - 48 is a key volume nod, historically. More often than not, such volume concentration points acts as magnets to the share price 5 - We hardly see any bear case on this board. If anything, there is one chap who keeps playing the violin on the ship's deck (daily, without ever changing the tune) with no regard to what's going on around him. The crowd is happy to follow. Classic inflection point tell, in my experience.

[jsredbird] 04/2/2022 14:44

Tong, what leads you to believe that target of 48 is in the works?

[wan] 04/2/2022 12:45

In considering healthcare generally (if you get my drift), after recent recruitment efforts, Amazon reported yesterday that they now have 1.6m employees, and that's excluding delivery drivers!

Given Amazons developments in healthcare, that's providing them with a lot of new healthcare customers (and providing healthcare benefits), especially when you add the employee family members in.

[tongosti] 04/2/2022 12:14

Ship heading further South - 48 beckons. Does one sleepwalk into you know what or manage risk? Tough choice ...

[wan] 04/2/2022 08:01

Many more diagnostic players have reported over the last few days.

In terms of COVID testing, The large companies have reported a mixed quarter picture compared to a year ago (when testing was extremely high), but acknowledged that testing demand has since increased due the omicron wave. And although the COVID testing situation is still very dynamic, they are factoring in an increase in testing (biased to the first half of 2022). One early example of the type of increase was from Quest Diagnostics who performed roughly 7.9 million COVID-19 molecular tests during Q4, but reported conducting a similar volume of testing in January 2022 alone. With several companies stating that they expect COVID PCR testing will play an ongoing role in the future, implying $100 million in revenue per quarter when COVID-19 becomes endemic.

Moving on, importantly the large diagnostic companies continue to report that their core businesses are performing very well and are growing, and have thus raised their outlooks for 2022.

[tongosti] 03/2/2022 10:19

There is a strong positive correlation between one's credibility and share price performance. This board will catch-up to this immutable truth as well.

[wan] 03/2/2022 09:36

Recall that EKF recently announced a strategic partnership agreement with Yourgene.

Within that announcement, it also included the following excerpts relating to cancer -

"Over time, EKF and Yourgene intend to provide further tests including in oncology, for which Yourgene has additional tests."

As part of the agreement, EKF will purchase state-of-the-art next generation sequencing ("NGS") technology ("Illumina NextSeq 550") and Yourgene's proprietary technology, to enable ADL to build NIPT screening services for a wide range of clinical conditions across reproductive health (including Down's Syndrome and other genetic disorders). It also provides the opportunity to use NGS technology independently to extend EKF's testing capabilities into other areas such as cardio-vascular disease testing (designed to determine the genetic predisposition towards cardiomyopathy, hypercholestermia, and other risk factors), hereditary cancer risk, genetic predisposition for Alzheimer's disease, Parkinson's disease and dementia.



EKF also supply a rapid CLIA waived test in the US for the early detection of colorectal cancer -

Staying with oncology, I note President Biden's important announcement yesterday -

Fact Sheet: President Biden Reignites Cancer Moonshot to End Cancer as We Know It
FEBRUARY 02, 2022

Today, President Biden is reigniting the Cancer Moonshot with renewed White House leadership of this effort. Because of recent progress in cancer therapeutics, diagnostics, and patient-driven care, as well as the scientific advances and public health lessons of the COVID-19 pandemic, it’s now possible to set ambitious goals: to reduce the death rate from cancer by at least 50 percent over the next 25 years, and improve the experience of people and their families living with and surviving cancer— and, by doing this and more, end cancer as we know it today.

The President and First Lady Jill Biden are also announcing a call to action on cancer screening to jumpstart progress on screenings that were missed as a result of the pandemic, and help ensure that everyone in the United States equitably benefits from the tools we have to prevent, detect, and diagnose cancer.

Mobilizing the Entire Government
Under the Biden-Harris Administration, the Cancer Moonshot will specifically:

Re-establish White House Leadership, with a White House Cancer Moonshot coordinator in the Executive Office of the President, to demonstrate the President and First Lady’s personal commitment to making progress and to leverage the whole-of-government approach and national response that the challenge of cancer demands.

Form a Cancer Cabinet, which will be convened by the White House, bringing together departments and agencies across government to address cancer on multiple fronts. These include the Department of Health and Human Services (HHS), Department of Veterans Affairs (VA), Department of Defense (DOD), Department of Energy (DOE), Department of Agriculture (USDA), Environmental Protection Agency (EPA), National Institutes of Health (NIH), National Cancer Institute (NCI), Food and Drug Administration (FDA), Centers for Medicare & Medicaid Services (CMS), Centers for Disease Control and Prevention (CDC), Office of Science and Technology Policy (OSTP), Domestic Policy Council (DPC), Gender Policy Council (GPC), Office of the First Lady (OFL), Office of the Vice President (OVP), Office of Management and Budget (OMB), Office of Legislative Affairs (OLA), Office of Public Engagement (OPE), along with additional members, as needed, to help establish and make progress on Cancer Moonshot goals.

Issue a Call to Action on Cancer Screening and Early Detection:
To deliver the message of urgency and increased access to get back on track after more than 9.5 million missed cancer screenings in the United States as a result of the COVID-19 pandemic. With regular recommended screenings, we can often catch cancer when there may be more effective treatment options or even prevent it from developing by removing pre-cancerous tissue.

To help ensure equitable access to screening and prevention through at-home screening (especially for colon cancer and HPV, the virus that causes cervical, head, neck and other cancers), mobile screening in communities without easy access to a clinic, through the community health networks we have built and strengthened during the COVID-19 pandemic, and other ways to reduce barriers to cancer screening.

Full release (worth reading all of it) -

[wan] 03/2/2022 07:42

Thermo Fisher Scientific Revenues Grow 1 Percent in Q4, 22 Percent in 2021
Feb 02, 2022

This article has been updated with information from Thermo Fisher's earnings call.

NEW YORK – Thermo Fisher Scientific on Wednesday morning reported a 1 percent increase in fourth quarter revenues and a 22 percent rise in full-year 2021 revenues. The company also raised its revenue and earnings guidance for 2022.

"We had an outstanding 2021, as we continued to execute our proven growth strategy, powered by our PPI Business System, and operated with speed at scale to help our customers and governments around the world advance their important work," said Marc Casper, Thermo Fisher's CEO, chairman, and president, in a statement.

"Customer demand is strong, our core business is performing very well, we're gaining market share, and we continue to play a leading role in the societal response to COVID-19," he added in a conference call to discuss the firm's financial results.

The company raised its revenue and earnings guidance for 2022. "This increase is a result of both the strong performance of our core business and an increase in the assumption for COVID-19 testing-related revenue," Casper said.

Thermo Fisher now expects $42 billion in revenues for the year, $1.5 billion more than previously. This represents 7 percent revenue growth over 2021 and 8 percent core organic revenue growth. The PPD clinical research business, in particular, is expected to deliver $6.5 billion in revenues in 2022.

CFO Stephen Williamson explained that four factors contributed to the revenue guidance raise: a $1 billion increase in anticipated COVID-19 testing revenues, a $900 million increase in core revenues, a $500 revenue decrease due to foreign exchange effects, and a $100 million increase in revenues from recently acquired recombinant protein manufacturer PeproTech.

He said the company currently assumes $1.75 billion of COVID-19 testing revenue in 2022 but could imagine "scenarios where testing demand could be higher."

Casper added that once COVID-19 becomes pandemic, Thermo Fisher expects about $100 million in related molecular diagnostic testing revenue per quarter, or $400 million per year. The company currently believes this will start happening in Q3 but Casper cautioned this assumption may change depending on "how the pandemic plays out."

Full article -

[tongosti] 02/2/2022 12:02

Gravity works.

[wan] 02/2/2022 07:12

PerkinElmer Q4 Revenues Inch Up Slightly
Feb 01, 2022

NEW YORK – PerkinElmer on Tuesday reported its fourth quarter revenues inched up less than 1 percent year over year.

On a conference call to discuss the firm's results, PerkinElmer CFO Jamey Mock noted that non-COVID-19-related revenues were up 11 percent year over year while COVID-19-related testing contributed $336 million in Q4. Year over year, however, COVID-19-related revenues were down more than $200 million.

He added that the firm saw strong demand for its COVID-19 PCR tests and extraction kits during Q4, especially in December "as Omicron spread across the globe."

On a non-COVID-19-related basis, its Diagnostics segment's revenues were up 14 percent year over year organically.

Lastly in Diagnostics, reproductive health sales grew in the low-double digits year over year organically, not including COVID-19 sales, Mock said, driven by market penetration, menu expansion, strong growth in PerkinElmer's lab business, and a "strong contribution" from its Vanadis noninvasive prenatal business.

For full-year 2021, PerkinElmer's revenues increased 34 percent to $5.07 billion from $3.78 billion in 2020 and beat the consensus Wall Street estimate of $4.97 billion.

The Discovery and Analytical Solutions segment sales grew 24 percent to $2.14 billion from $1.72 billion in 2020, while the Diagnostics segment sales were up 42 percent to $2.93 billion from $2.07 billion.

COVID-19-related revenues totalled about $1.6 billion for the year, Mock said.

Full article -

[tongosti] 01/2/2022 08:32

Laughing stock really.

[wan] 01/2/2022 07:42

Investors should keep the paradigm shift in consumer-initiated lab testing firmly in mind, with EKF's 'proprietary' CLIA laboratory testing portfolio beyond COVID-19 assays, already set for expansion.

The size of the market and the growth on offer is exemplified by the following collaboration -

Quest Partners With Walmart to Offer Consumer-Initiated Testing
Jan 31, 2022

According to a recent Quest Health Trends report, 60 percent of US adults said they have skipped or delayed some in-person medical treatments or appointments due to the COVID-19 pandemic.

"While many are too busy or face barriers to engage in in-person doctors' appointments, others choose to proactively arm themselves with diagnostic insights before engaging with one," Steve Rusckowski, Quest's chairman, president, and CEO, said in a statement. "Our close relationship with Walmart has allowed us to create a solution that is high quality and accessible. Powered by QuestDirect from Quest Diagnostics, this new solution can broaden access to laboratory testing and health insights, and support for a range of conditions for potentially better outcomes."
Full article -

Also of note within the above - Customers can then either schedule an appointment at a Quest draw center or arrange for delivery of an at-home collection kit, depending on the test.

EKF is already experienced and active in the field of at-home collection kits.